The paper, which involved collaborative between the University of Manchester and AstraZeneca, shows that the information on lung density that can be provided using MRI is equivalent to that available from CT, but without the ionising radiation burden.
In a further publication in the journal COPD, Bioxydyn’s proprietary Pulmolux platform has been shown to be sensitive to the T1 biomarker. The publication demonstrates that T1 is affected in COPD patients and hence Magnetic resonance imaging (MRI) may provide attractive biomarkers for assessment of pulmonary disease in clinical trials as it is free from ionizing radiation, minimally invasive and allows regional information. lung MRI T1 mapping shows potential as a repeatable, radiation free, non-invasive imaging technique in the evaluation of COPD.
Dr Mark Rahn, partner of investor in Bioxydyn, MTI Ventures, commented “Data demonstrating the power of non-ionising MRI imaging in the lung is coming in regularly now, and each new demonstration reinforces our view of exciting prospects for Bioxydyn”.
Prof Geoff Parker, CEO of Bioxydyn commented “Bioxydyn’s lung MRI applications are reaching an audience of key opinion leaders who are using our technologies in increasingly important studies of lung disease. These studies indicate the power of MRI in the lung and Bioxydyn’s leading role in this emerging field."